<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TERBINAFINE HYDROCHLORIDE - terbinafine hydrochloride tablet </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<br>These highlights do not include all the information needed to use Terbinafine Hydrochloride Tablets safely and effectively. See full prescribing information for Terbinafine Hydrochloride.<br><br>Terbinafine Hydrochloride (terbinafine hydrochloride) Tablet for oral use.<br>Initial U.S. Approval: 1992</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> Warnings and Precautions </p>
<p class="Highlighta"> Smell Disturbance Including <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">Loss of Smell</span> <a href="#bb0964ed-31b7-4dff-b68d-f2110b7b8486">(5.3)</a>                  03/2011 </p>
<p class="Highlighta"> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span> Including <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Loss of Taste</span> <a href="#b5a58af3-bf0c-48ce-89b9-b083c55eccb3">(5.2)</a>                   10/2010 </p>
<p class="Highlighta"> <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">Depressive Symptoms</span> <a href="#b4889d69-a394-4d53-8bcc-4d44978ea83d">(5.4)</a>                                                   10/2010 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"> Terbinafine hydrochloride tablets are an allylamine antifungal indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> of the toenail or fingernail due to dermatophytes (<span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium).  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li> Fingernail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>: One 250 mg tablet, once daily for 6 weeks.</li>
<li> Toenail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>: One 250 mg tablet, once daily for 12 weeks.</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"> Tablet, 250 mg  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"> Terbinafine hydrochloride tablets are contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to oral terbinafine because of the risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. <a href="#b74b08d5-599b-407f-be09-c73f826225da">(4)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Liver failure</span>, sometimes leading to liver transplant or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has occurred with the use of oral terbinafine. Obtain pretreatment serum transaminases. Discontinue terbinafine hydrochloride tablets if <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> develops. <a href="#b5d39d7f-784f-47a9-9a89-991850b941a8">(5.1,</a><a href="#bb5458b5-d357-43f6-aeda-f49e6a4ed13e">5.8)</a>
</li>
<li> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste disturbance</span>, including <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, has been reported with the use of terbinafine hydrochloride tablets. <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste disturbance</span> can be severe, may be prolonged, or may be permanent. Discontinue terbinafine hydrochloride tablets if <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span> occurs. <a href="#b5a58af3-bf0c-48ce-89b9-b083c55eccb3">(5.2)</a>
</li>
<li> Smell disturbance, including <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">loss of smell</span>, has been reported with the use of terbinafine hydrochloride tablets. Smell disturbance may be prolonged, or may be permanent. Discontinue terbinafine hydrochloride tablets if smell disturbance occurs. <a href="#bb0964ed-31b7-4dff-b68d-f2110b7b8486">(5.3)</a>
</li>
<li> <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">Depressive symptoms</span> have been reported with terbinafine use. Prescribers should be alert to development of <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>. <a href="#b4889d69-a394-4d53-8bcc-4d44978ea83d">(5.4)</a>
</li>
<li> Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> has been reported. If the neutrophil count is ≤ 1,000 cells/mm<span class="Sup">3</span>, terbinafine hydrochloride tablets should be discontinued. <a href="#bd35dcd8-5a28-4865-83df-75263cabb6e1">(5.5)</a>
</li>
<li> <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported with oral terbinafine use. If progressive <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> occurs, treatment with terbinafine hydrochloride tablets should be discontinued. <a href="#b9abef98-ce4b-4165-8cca-5e5a27c879fa">(5.6)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta"> Common (&gt;2% in patients treated with terbinafine hydrochloride tablets) reported adverse events include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, liver enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>. <a href="#b4e6135e-b7db-42e6-a103-6f6f2360d505">(6.1)</a><br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Harris Pharmaceutical at 1-877-794-3376 or FDA at 1-800-FDA-1088 or <span class="Bold Italics">www.fda.gov/medwatch.</span></span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta"> Terbinafine is an inhibitor of CYP4502D6 isozyme and has an effect on metabolism of desipramine, cimetidine, fluconazole, cyclosporine, rifampin, and caffeine. <a href="#bd06b787-4eb1-4bb7-b8e5-f682380d76e4">(7.1)</a> </p></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1  INDICATIONS &amp; USAGE
</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2  DOSAGE &amp; ADMINISTRATION
</span></a></h1>
<h1><a href="#section-3" class="toc"><span class="Bold">3  DOSAGE FORMS &amp; STRENGTHS
</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4  CONTRAINDICATIONS
</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5  WARNINGS AND PRECAUTIONS
</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold Italics">5.1 Hepatotoxicity 
</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold Italics">5.2 <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span> Including <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Loss of Taste</span> 
</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold Italics">5.3 Smell Disturbance Including <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">Loss of Smell</span> 
</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold Italics">5.4 <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">Depressive Symptoms</span> 
</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold Italics">5.5 Hematologic Effects 
</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold Italics">5.6 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> 
</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold Italics">5.7 <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">Lupus Erythematosus</span> 
</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold Italics">5.8 Laboratory Monitoring 
</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6  ADVERSE REACTIONS
</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold Italics">6.1 Clinical Studies Experience 
</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold Italics">6.2 Postmarketing Experience 
</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7  DRUG INTERACTIONS
</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold Italics">7.1 Drug-Drug Interactions 
</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold Italics">7.2 Food Interactions 
</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8  USE IN SPECIFIC POPULATIONS
</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold Italics">8.1 Pregnancy 
</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold Italics">8.3 Nursing Mothers 
</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold Italics">8.4 Pediatric Use 
</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold Italics">8.5 Geriatric Use 
</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10  OVERDOSAGE
</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11  DESCRIPTION
</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12  CLINICAL PHARMACOLOGY
</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold Italics">12.1 Mechanism of Action 
</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold Italics">12.2 Pharmacodynamics 
</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold Italics">12.3 Pharmacokinetics 
</span></a></h2>
<h2><a href="#section-11.4" class="toc"><span class="Bold Italics">12.4 Microbiology 
</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13  NONCLINICAL TOXICOLOGY
</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold Italics">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 
</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold Italics">13.2 Animal toxicology and/or pharmacology 
</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14  CLINICAL STUDIES
</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17  PATIENT COUNSELING INFORMATION
</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1><span class="Bold">1  INDICATIONS &amp; USAGE
</span></h1>
<p class="First">Terbinafine hydrochloride (HCl) tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> of the toenail or fingernail due to dermatophytes (<span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium).</p>
<p>Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1><span class="Bold">2  DOSAGE &amp; ADMINISTRATION
</span></h1>
<p class="First">Fingernail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>: One 250 mg tablet once daily for 6 weeks.</p>
<p>Toenail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>: One 250 mg tablet once daily for 12 weeks.</p>
<p>The optimal clinical effect is seen some months after mycological cure and cessation of treatment. This is related to the period required for outgrowth of healthy nail.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1><span class="Bold">3  DOSAGE FORMS &amp; STRENGTHS
</span></h1>
<p class="First">Tablet, 250 mg white to off-white round tablets debossed ‘AN’ above ‘543’ on one side and plain on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="b74b08d5-599b-407f-be09-c73f826225da"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4  CONTRAINDICATIONS
</span></h1>
<p class="First">Terbinafine HCl tablets are contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to oral terbinafine because of the risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1><span class="Bold">5  WARNINGS AND PRECAUTIONS
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="b5d39d7f-784f-47a9-9a89-991850b941a8"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold Italics">5.1 Hepatotoxicity 
</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, some leading to liver transplant or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have occurred with the use of terbinafine HCl tablets in individuals with and without pre-existing liver disease.</p>
<p>In the majority of liver cases reported in association with terbinafine HCl use, the patients had serious underlying systemic conditions. The severity of hepatic events and/or their outcome may be worse in patients with active or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>. Treatment with terbinafine HCl tablets should be discontinued if biochemical or clinical evidence of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> develops.</p>
<p>Terbinafine HCl tablets are not recommended for patients with chronic or active liver disease. Before prescribing terbinafine HCl tablets, pre-existing liver disease should be assessed. Hepatotoxicity may occur in patients with and without pre-existing liver disease. Patients prescribed terbinafine HCl tablets should be warned to report immediately to their physician any symptoms of persistent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, right <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> stools. Patients with these symptoms should discontinue taking oral terbinafine, and the patient’s liver function should be immediately evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b5a58af3-bf0c-48ce-89b9-b083c55eccb3"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold Italics">5.2 <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span> Including <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Loss of Taste</span> 
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste disturbance</span>, including <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, has been reported with the use of terbinafine HCl tablets. It can be severe enough to result in decreased food intake, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, and <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>. <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste disturbance</span> may resolve within several weeks after discontinuation of treatment, but may be prolonged (greater than one year), or may be permanent. If symptoms of a <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span> occur, terbinafine HCl tablets should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bb0964ed-31b7-4dff-b68d-f2110b7b8486"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold Italics">5.3 Smell Disturbance Including <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">Loss of Smell</span> 
</span></h2>
<p class="First">Smell disturbance, including <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">loss of smell</span>, has been reported with the use of terbinafine HCl tablets. Smell disturbance may resolve after discontinuation of treatment, but may be prolonged (greater than one year), or may be permanent. If symptoms of a smell disturbance occur, terbinafine HCl tablets should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b4889d69-a394-4d53-8bcc-4d44978ea83d"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold Italics">5.4 <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">Depressive Symptoms</span> 
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">Depressive symptoms</span> have occurred during postmarketing use of terbinafine. Prescribers should be alert to <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>, and patients should be instructed to report <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> to their physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bd35dcd8-5a28-4865-83df-75263cabb6e1"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold Italics">5.5 Hematologic Effects 
</span></h2>
<p class="First">Transient decreases in absolute lymphocyte counts (ALC) have been observed in controlled clinical trials. In placebo-controlled trials, 8/465  terbinafine HCl-treated patients (1.7%) and 3/137 placebo-treated patients (2.2%) had decreases in ALC to below 1000/mm<span class="Sup">3</span> on two or more occasions. In patients with known or suspected <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>, physicians should consider monitoring complete blood counts if treatment continues for more than six weeks. Cases of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported. These were reversible upon discontinuation of terbinafine HCl, with or without supportive therapy. If clinical signs and symptoms suggestive of <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> occur, a complete blood count should be obtained. If the neutrophil count is ≤1,000 cells/mm<span class="Sup">3</span>, terbinafine HCl should be discontinued and supportive management started.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b9abef98-ce4b-4165-8cca-5e5a27c879fa"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold Italics">5.6 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> 
</span></h2>
<p class="First">There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>). If progressive <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> occurs, treatment with terbinafine HCl tablets should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b3de5dae-5e52-4b7d-ab46-9a58823a87b6"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold Italics">5.7 <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">Lupus Erythematosus</span> 
</span></h2>
<p class="First">During post-marketing experience, precipitation and exacerbation of cutaneous and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> have been reported in patients taking terbinafine HCl tablets. Terbinafine HCl tablets should be discontinued in patients with clinical signs and symptoms suggestive of <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bb5458b5-d357-43f6-aeda-f49e6a4ed13e"></a><a name="section-5.8"></a><p></p>
<h2><span class="Bold Italics">5.8 Laboratory Monitoring 
</span></h2>
<p class="First">Measurement of serum transaminases (ALT and AST) is advised for all patients before taking terbinafine HCl tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1><span class="Bold">6  ADVERSE REACTIONS
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="b4e6135e-b7db-42e6-a103-6f6f2360d505"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold Italics">6.1 Clinical Studies Experience 
</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The most frequently reported adverse events observed in the three US/Canadian placebo-controlled trials are listed in the table below. The adverse events reported encompass <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), liver test abnormalities, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbances</span>. Changes in the ocular lens and retina have been reported following the use of terbinafine HCl tablets in controlled trials. The clinical significance of these changes is unknown. In general, the adverse events were mild, transient, and did not lead to discontinuation from study participation.</p>
<a name="ibc288b9d-7a0d-4389-8819-d8e2d0c0c841"></a><table frame="void" width="595">
<thead><tr class="First Last">
<td class="BotruleLruleRruleToprule" align="center" colspan="2" valign="top"><span class="Bold">Adverse Event</span></td>
<td class="BotruleLruleRruleToprule" align="center" colspan="2" valign="top"><span class="Bold">Discontinuation</span></td>
</tr></thead>
<tbody>
<tr class="First"><td class="BotruleLruleRruleToprule" align="left" valign="top"></td></tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">
<span class="Bold">Terbinafine</span><span class="Bold">HCl</span>
</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">
<span class="Bold">Terbinafine</span><span class="Bold">HCl</span>
</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle"><span class="Bold">(%)</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle"><span class="Bold">(%)</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"><span class="Bold">(%)</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"><span class="Bold">(%)</span></td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"><span class="Bold">n=465</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"><span class="Bold">n=137</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"><span class="Bold">n=465</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"><span class="Bold">n=137</span></td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">12.9</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">9.5</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.2</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Symptoms</span>:</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">5.6</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2.9</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.6</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">4.3</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2.9</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.4</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2.4</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">1.5</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.4</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2.6</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2.9</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.2</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2.2</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2.2</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Dermatological Symptoms:</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">5.6</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">2.2</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">0.9</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">0.7</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">2.8</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">1.5</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">0.2</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> </td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">1.1</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">0.0</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">0.0</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="bottom">Liver Enzyme </td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">3.3</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">1.4</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">0.2</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">0.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Abnormalities*</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2.8</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.7</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.2</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbance</span> </td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">1.1</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">1.5</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.9</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0.0</td>
</tr>
</tbody>
</table>
<p>* Liver enzyme abnormalities ≥2x the upper limit of normal range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold Italics">6.2 Postmarketing Experience 
</span></h2>
<p class="First">The following adverse events have been identified during post-approval use of terbinafine HCl. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Adverse events, based on worldwide experience with terbinafine HCl tablets use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, some leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or liver transplant, serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) [see <span class="Italics"><a href="#b5d39d7f-784f-47a9-9a89-991850b941a8">Warnings and Precautions (5.1,</a></span><span class="Italics"><a href="#bd35dcd8-5a28-4865-83df-75263cabb6e1">5.5,</a></span><span class="Italics"> and </span><span class="Italics"><a href="#b9abef98-ce4b-4165-8cca-5e5a27c879fa">5.6)</a></span>].</p>
<p>Psoriasiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> or <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>, <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span> and precipitation and exacerbation of cutaneous and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> have been reported in patients taking terbinafine HCl [see <span class="Italics"><a href="#b3de5dae-5e52-4b7d-ab46-9a58823a87b6">Warnings and Precautions (5.7)</a></span>].</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, including <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, have been reported with the use of terbinafine HCl tablets. It can be severe enough to result in decreased food intake, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, and <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> [see <span class="Italics"><a href="#b5a58af3-bf0c-48ce-89b9-b083c55eccb3">Warnings and Precautions (5.2)</a></span>]. <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">Depressive symptoms</span> independent of <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span> have been reported with use of terbinafine HCl tablets. In some cases, <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> have been reported to subside with discontinuance of therapy and to recur with reinstitution of therapy [see <span class="Italics"><a href="#b4889d69-a394-4d53-8bcc-4d44978ea83d">Warnings and Precautions (5.4)</a></span>]. Cases of smell disturbance, including <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">smell loss</span>, have been reported with the use of terbinafine HCl tablets [see <span class="Italics"><a href="#bb0964ed-31b7-4dff-b68d-f2110b7b8486">Warnings and Precautions (5.3)</a></span>].</p>
<p>Other adverse reactions which have been reported include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, reduced visual acuity, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reaction, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, and increased <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">blood creatine phosphokinase</span>.</p>
<p>Altered <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (prolongation and reduction) in patients concomitantly treated with warfarin has been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1><span class="Bold">7  DRUG INTERACTIONS
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="bd06b787-4eb1-4bb7-b8e5-f682380d76e4"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold Italics">7.1 Drug-Drug Interactions 
</span></h2>
<p class="First"><span class="Italics">In vivo</span> studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of terbinafine HCl should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in C<span class="Sub">max</span> and a 5-fold increase in AUC. In this study, these effects were shown to persist at the last observation at 4 weeks after discontinuation of terbinafine HCl tablets. In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan, terbinafine increases the dextromethorphan/dextrorphan metabolite ratio in urine by 16- to 97-fold on average. <span class="Italics">In vitro</span> studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, cyclosporine, cisapride and fluvastatin. <span class="Italics">In vivo</span> drug-drug interaction studies conducted in healthy volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. Terbinafine decreases the clearance of caffeine by 19%. Terbinafine increases the clearance of cyclosporine by 15%.</p>
<p>The influence of terbinafine on the pharmacokinetics of fluconazole, trimethoprim, sulfamethoxazole, zidovudine or theophylline was not considered to be clinically significant. Co-administration of a single dose of fluconazole (100mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine C<span class="Sub">max</span> and AUC, respectively. Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on this finding, it is likely that other inhibitors of both CYP2C9 and CYP3A4 (e.g., ketoconazole, amiodarone) may also lead to a substantial increase in the systemic exposure (C<span class="Sub">max</span> and AUC) of terbinafine.</p>
<p>There have been spontaneous reports of increase or decrease in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between terbinafine HCl tablets and these changes has not been established.</p>
<p>Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. Terbinafine clearance is unaffected by cyclosporine.</p>
<p>There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold Italics">7.2 Food Interactions 
</span></h2>
<p class="First">An evaluation of the effect of food on terbinafine HCl tablets was conducted. An increase of less than 20% of the AUC (i.e. area under the curve) of terbinafine was observed when terbinafine HCl tablets were administered with food. Terbinafine HCl tablets can be taken with or without food.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1><span class="Bold">8  USE IN SPECIFIC POPULATIONS
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold Italics">8.1 Pregnancy 
</span></h2>
<p class="First"><span class="Bold Italics">Pregnancy Category B:</span> There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> can be postponed until after pregnancy is completed, it is recommended that terbinafine HCl not be initiated during pregnancy.</p>
<p>Oral reproduction studies have been performed in rabbits and rats at doses up to 300 mg/kg/day (12x to 23x the MRHD, in rabbits and rats, respectively, based on BSA) and have revealed no evidence of impaired fertility or harm to the fetus due to terbinafine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold Italics">8.3 Nursing Mothers 
</span></h2>
<p class="First">After oral administration, terbinafine is present in breast milk of nursing mothers. The ratio of terbinafine in milk to plasma is 7:1. Treatment with terbinafine HCl is not recommended in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold Italics">8.4 Pediatric Use 
</span></h2>
<p class="First">The safety and efficacy of terbinafine HCl tablets have not been established in pediatric patients with <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold Italics">8.5 Geriatric Use 
</span></h2>
<p class="First">Clinical studies of terbinafine HCl tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10  OVERDOSAGE
</span></h1>
<p class="First">Clinical experience regarding <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with oral terbinafine is limited. Doses up to 5 grams (20 times the therapeutic daily dose) have been taken without inducing serious adverse reactions. The symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, frequent urination, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11  DESCRIPTION
</span></h1>
<p class="First">Terbinafine HCl tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.</p>
<p>Chemically, terbinafine hydrochloride is (E)-<span class="Italics">N</span>-(6,6-dimethyl-2-hepten-4-ynyl)-<span class="Italics">N</span>-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C<span class="Sub">21</span>H<span class="Sub">26</span>CIN with a molecular weight of 327.90, and the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aa9f660f-29e6-42fe-ba66-ee9387ce0385&amp;name=terbinafine-01.jpg"></div>
<p>Terbinafine hydrochloride is a white to off-white fine crystalline powder. It is freely soluble in methanol and methylene chloride, soluble in ethanol, and slightly soluble in water.</p>
<p><span class="Bold Italics">Each tablet contains: </span></p>
<p><span class="Italics">Active Ingredients:</span> terbinafine hydrochloride (equivalent to 250 mg base)</p>
<p><span class="Italics">Inactive Ingredients:</span> colloidal silicon dioxide, NF; hypromellose, USP; magnesium stearate, NF; microcrystalline cellulose, NF; and sodium starch glycolate, NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12  CLINICAL PHARMACOLOGY
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold Italics">12.1 Mechanism of Action 
</span></h2>
<p class="First">Terbinafine is an allylamine antifungal [see <span class="Italics"><a href="#ba11383a-c446-4902-9bb3-8e67a4c143fc">Clinical Pharmacology (12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold Italics">12.2 Pharmacodynamics 
</span></h2>
<p class="First">The pharmacodynamics of terbinafine HCl is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2><span class="Bold Italics">12.3 Pharmacokinetics 
</span></h2>
<p class="First">Following oral administration, terbinafine is well absorbed (&gt;70%) and the bioavailability of terbinafine HCl tablets as a result of first-pass metabolism is approximately 40%. Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC (area under the curve) is approximately 4.56 mcg.h/mL. An increase in the AUC of terbinafine of less than 20% is observed when terbinafine HCl tablets are administered with food.</p>
<p>In plasma, terbinafine is &gt;99% bound to plasma proteins and there are no specific binding sites. At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours. Terbinafine is distributed to the sebum and skin. A terminal half-life of 200 to 400 hours may represent the slow elimination of terbinafine from tissues such as skin and adipose. Prior to excretion, terbinafine is extensively metabolized by at least seven CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19. No metabolites have been identified that have antifungal activity similar to terbinafine. Approximately 70% of the administered dose is eliminated in the urine.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance ≤50 mL/min) or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>, the clearance of terbinafine is decreased by approximately 50% compared to normal volunteers. No effect of gender on the blood levels of terbinafine was detected in clinical trials. No clinically relevant age-dependent changes in steady-state plasma concentrations of terbinafine have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ba11383a-c446-4902-9bb3-8e67a4c143fc"></a><a name="section-11.4"></a><p></p>
<h2><span class="Bold Italics">12.4 Microbiology 
</span></h2>
<p class="First">Terbinafine, an allylamine antifungal, inhibits biosynthesis of ergosterol, an essential component of fungal cell membrane, via inhibition of squalene epoxidase enzyme. This results in fungal <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span> primarily due to the increased membrane permeability mediated by the accumulation of high concentrations of squalene but not due to ergosterol deficiency. Depending on the concentration of the drug and the fungal species test <span class="Italics">in vitro</span>, terbinafine hydrochloride may be fungicidal. However, the clinical significance of <span class="Italics">in vitro</span> data is unknown.</p>
<p>Terbinafine has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<p><span class="Italics">Trichophyton mentagrophytes </span></p>
<p><span class="Italics">Trichophyton rubrum </span></p>
<p>The following <span class="Italics">in vitro</span> data are available, but their clinical significance is unknown. <span class="Italics">In vitro</span>, terbinafine exhibits satisfactory MIC’s against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and efficacy of terbinafine in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans </span></p>
<p><span class="Italics">Epidermophyton floccosum </span></p>
<p><span class="Italics">Scopulariopsis brevicaulis </span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13  NONCLINICAL TOXICOLOGY
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold Italics">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 
</span></h2>
<p class="First">In a 28-month oral carcinogenicity study in rats, an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> was observed in males at the highest dose tested, 69 mg/kg/day [2x the Maximum Recommended Human Dose (MRHD) based on AUC comparisons of the parent terbinafine]; however, even though dose-limiting toxicity was not achieved at the highest tested dose, higher doses were not tested.</p>
<p>The results of a variety of <span class="Italics">in vitro</span> (mutations in <span class="Italics">E. coli</span> and <span class="Italics">S. typhimurium</span>, DNA repair in rat hepatocytes, mutagenicity in Chinese hamster fibroblasts, chromosome aberration and sister chromatid exchanges in Chinese hamster lung cells), and <span class="Italics">in vivo</span> (chromosome aberration in Chinese hamsters, micronucleus test in mice) genotoxicity tests gave no evidence of a mutagenic or clastogenic potential.</p>
<p>Oral reproduction studies in rats at doses up to 300 mg/kg/day (approximately 12x the MRHD based on body surface area comparisons, BSA) did not reveal any specific effects on fertility or other reproductive parameters. Intravaginal application of terbinafine hydrochloride at 150 mg/day in pregnant rabbits did not increase the incidence of abortions or premature deliveries nor affect fetal parameters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2><span class="Bold Italics">13.2 Animal toxicology and/or pharmacology 
</span></h2>
<p class="First">A wide range of <span class="Italics">in vivo</span> studies in mice, rats, dogs, and monkeys, and <span class="Italics">in vitro</span> studies using rat, monkey, and human hepatocytes suggest that peroxisome proliferation in the liver is a rat-specific finding. However, other effects, including increased liver weights and APTT, occurred in dogs and monkeys at doses giving Css trough levels of the parent terbinafine 2 to 3x those seen in humans at the MRHD. Higher doses were not tested.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1><span class="Bold">14  CLINICAL STUDIES
</span></h1>
<p class="First">The efficacy of terbinafine HCl tablets in the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> is illustrated by the response of patients with toenail and/or fingernail <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> who participated in three US/Canadian placebo-controlled clinical trials.</p>
<p>Results of the first toenail study, as assessed at week 48 (12 weeks of treatment with 36 weeks follow-up after completion of therapy), demonstrated mycological cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 70% of patients. Fifty-nine percent (59%) of patients experienced effective treatment (mycological cure plus 0% nail involvement or &gt;5mm of new unaffected nail growth); 38% of patients demonstrated mycological cure plus clinical cure (0% nail involvement).</p>
<p>In a second toenail study of dermatophytic <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>, in which non-dermatophytes were also cultured, similar efficacy against the dermatophytes was demonstrated. The pathogenic role of the non-dermatophytes cultured in the presence of dermatophytic <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> has not been established. The clinical significance of this association is unknown.</p>
<p>Results of the fingernail study, as assessed at week 24 (6 weeks of treatment with 18 weeks follow-up after completion of therapy), demonstrated mycological cure in 79% of patients, effective treatment in 75% of the patients, and mycological cure plus clinical cure in 59% of the patients.</p>
<p>The mean time to overall success was approximately 10 months for the first toenail study and 4 months for the fingernail study. In the first toenail study, for patients evaluated at least six months after achieving clinical cure and at least one year after completing terbinafine HCl therapy, the clinical relapse rate was approximately 15%.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING</span></h1>
<p class="First">Terbinafine HCl tablets <span class="Bold">250 mg </span>are supplied as white to off-white, round tablets debossed ‘AN’ above ‘543’ on one side and plain on the other side.</p>
<p>Bottles of 30 tablets 				NDC 67405-543-03</p>
<p>Bottles of 100 tablets 				NDC 67405-543-10</p>
<p>Store tablets at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]; in a tight container. Protect from light.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17  PATIENT COUNSELING INFORMATION
</span></h1>
<p class="First"><span class="Italics">[See FDA</span><span class="Italics"><a href="#b6e2a21d-f8d4-4497-9042-7d661a015c80">-Approved Patient Labeling (Patient Information)</a></span><span class="Italics">] </span></p>
<p>Patients taking terbinafine HCl tablets should receive the following information and instructions:</p>
<ul class="Disc">
<li>Patients should take one 250 mg tablet once daily for 6 weeks for treatment of fingernail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> or once daily for 12 weeks for treatment of toenail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>. The optimal clinical effect is seen some months after mycological cure and cessation of treatment due to the time period required for outgrowth of healthy nail.</li>
<li>Patients should be  advised to immediately report to their physician any symptoms of persistent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, right <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> stools. Terbinafine HCl tablets treatment should be discontinued.</li>
<li>Patients should be advised to report to their physician any signs of <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, smell disturbance and/or <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>. Terbinafine HCl tablets treatment should be discontinued.</li>
<li>Patients should be advised to immediately report to their physician or get emergency help if they experience any of the following symptoms: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, mouth sores, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> and <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of skin, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, lips, tongue, or throat, difficulty swallowing or breathing. Terbinafine HCl tablets treatment should be discontinued.</li>
<li>Patients should be advised to report to their physician any symptoms of new onset or worsening <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>. Symptoms can include <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, loss of pigment, and unusual <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> that can result in a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Terbinafine HCl treatment should be discontinued.</li>
<li>Measurement of serum transaminases (ALT and AST) is advised for all patients before taking terbinafine HCl tablets.</li>
<li>Patients should be advised that if they forget to take terbinafine HCl tablets, to take their tablets as soon as they remember, unless it is less than four hours before the next dose is due. Patients should also be advised that if they take too many terbinafine HCl tablets they should call their physician.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">Terbinafine Hydrochloride Tablets</span></p>
<p>Read this Patient Information before you start taking terbinafine HCl and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is terbinafine HCl? </span></p>
<p>Terbinafine HCl is a prescription antifungal medicine used to treat <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the fingernails and toenails (<span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>).</p>
<p>Your doctor should do tests to check you for <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> of your nails before you start terbinafine HCl.</p>
<p>It is not known if terbinafine HCl is safe and effective in children for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>.</p>
<p><span class="Bold">Who should not take terbinafine HCl? </span></p>
<p>Do not take terbinafine HCl tablets if you are allergic to terbinafine hydrochloride when taken by mouth.</p>
<p><span class="Bold">What should I tell my doctor before taking terbinafine HCl? </span></p>
<p><span class="Bold">Before you take terbinafine HCl, tell your doctor if you: </span></p>
<ul class="Disc">
<li>have or had liver problems</li>
<li>have a weakened immune system (immunocompromised)</li>
<li>have lupus (an autoimmune disease)</li>
<li>have kidney problems</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. It is not known if terbinafine HCl will harm your unborn baby. You should not start using terbinafine HCl during pregnancy without talking with your doctor.</li>
<li>are breast-feeding or plan to breast-feed. Some terbinafine HCl passes into your milk and may harm your baby. Talk to your doctor about the best way to feed your baby if you take terbinafine HCl.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and nonprescription medicines, vitamins, and herbal supplements. Terbinafine HCl may affect the way other medicines work and other medicines may affect how terbinafine HCl works. Especially tell your doctor if you take:</p>
<ul class="Disc">
<li>a medicine for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>a medicine for high blood pressure</li>
<li>a medicine for heart problems</li>
<li>desipramine (Norpramin)</li>
<li>caffeine</li>
<li>cyclosporine (Gengraf, Neoral, Sandimmune)</li>
<li>fluconazole (Diflucan)</li>
<li>rifampin (Rifater, Rifamate, Rimactane, Rifadine)</li>
<li>cimetidine (Tagamet)</li>
</ul>
<p>If you are not sure if your medicine is one listed above, ask your doctor or pharmacist.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take terbinafine HCl? </span></p>
<ul class="Disc">
<li>Take terbinafine HCl exactly as your doctor tells you to take it.</li>
<li>Terbinafine HCl comes as a tablet that you take by mouth.</li>
<li>
<span class="Bold">Terbinafine HCl is usually taken: </span><ul class="Disc">
<li><span class="Bold">1 time each day for 6 weeks to treat <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of your fingernail, or </span></li>
<li><span class="Bold">1 time each day for 12 weeks to treat <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of your toenail</span></li>
</ul>
</li>
<li>You can take terbinafine HCl with or without food.</li>
<li>If you forget to take terbinafine HCl, take your tablets as soon as you remember, unless it is less than 4 hours before your next dose is due. In this case, wait and take your next dose at the usual time.</li>
<li>If you take too much terbinafine HCl call your doctor. You may have the following symptoms:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>frequent urination</li>
</ul>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of terbinafine HCl?</span></p>
<p><span class="Bold">Terbinafine HCl may cause serious side effects, including:</span></p>
<ul class="Disc"><li>
<span class="Bold">liver problems that can lead to the need for liver transplant, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> Tell your doctor right away if you get any of these symptoms of a liver problem:
						
						<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>poor appetite</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>upper right stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>yellowing of your skin or eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>dark (tea-colored) urine</li>
<li><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> or light colored stools</li>
</ul>
</li></ul>
<p>Your doctor should do a blood test to check you for liver problems before you take terbinafine HCl.</p>
<ul class="Disc">
<li>
<span class="Bold">change in taste or <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span></span> may happen with terbinafine HCl. This usually improves within several weeks after stopping terbinafine HCl, but may last for a long time or may become permanent. Tell your doctor if you have:
								<ul class="Disc">
<li>change in taste or <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span></li>
<li>poor appetite</li>
<li>unwanted <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, or</li>
<li>change in mood or <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span></li>
</ul>
</li>
<li>
<span class="Bold">change in smell or <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">loss of smell</span></span> may happen with terbinafine HCl. This may improve after stopping terbinafine HCl, but may last for a long time or may become permanent.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>. Tell your doctor right away if you have any of these signs or symptoms: </span><ul class="Disc">
<li>feel sad or worthless</li>
<li>change in sleep pattern</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">loss of energy</span> or interest in daily activities</li>
<li><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span></li>
</ul>
</li>
<li>
<span class="Bold">serious skin or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> Tell your doctor right away or get emergency help if you get any of these symptoms:
								<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, sores in your mouth, or your skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and peels</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips, tongue or throat</li>
<li>trouble swallowing or breathing</li>
</ul>
</li>
<li>
<span class="Bold">new or worsening lupus (an autoimmune disease).</span> Stop taking terbinafine HCl and tell your doctor if you experience any of the following:
								<ul class="Disc">
<li>progressive <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> that is scaly, red, shows <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span>, or loss of pigment</li>
<li>unusual sensitivity to the sun that can lead to a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
</ul>
</li>
</ul>
<p>The most common side effects of terbinafine HCl include: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, liver enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of terbinafine HCl. For information, ask your doctor or pharmacist.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects.</span></p>
<p><span class="Bold">You may report side effects to FDA at 1-800-FDA-1088. </span></p>
<p><span class="Bold"><br></span><span class="Bold">How do I store terbinafine HCl? </span></p>
<ul class="Disc">
<li>Store terbinafine HCl at a temperature below 77° F (25° C).</li>
<li>Keep terbinafine HCl in a tightly closed container and away from light.</li>
</ul>
<p><span class="Bold">Keep terbinafine HCl and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of terbinafine HCl.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in Patient Information. Do not use terbinafine HCl for a condition for which it was not prescribed. Do not give terbinafine HCl to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Patient Information summarizes the most important information about terbinafine HCl. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about terbinafine HCl that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in terbinafine HCl? </span></p>
<p>Active ingredient: terbinafine hydrochloride.</p>
<p>Inactive ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose and sodium starch glycolate.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1><span class="Bold"></span></h1>
<p class="First">Manufactured for:</p>
<p><span class="Bold">HARRIS Pharmaceutical, Inc.</span></p>
<p>Fort Myers, Florida  33908-8238</p>
<p>By:</p>
<p><span class="Bold">Amneal Pharmaceuticals</span></p>
<p>Paterson, New Jersey  07504</p>
<p>Rev. 06/2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30 Tablet Label</span></p>
<p><span class="Bold">HARRIS</span><br>PHARMACEUTICAL</p>
<p><br></p>
<p><span class="Bold">TERBINAFINE<br>HYDROCHLORIDE</span><br>TABLETS</p>
<p><span class="Italics">equivalent to</span><br><span class="Bold">250 mg</span><br><span class="Italics">base</span></p>
<p><span class="Bold">30 tablets</span> (white)<br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="55289054 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aa9f660f-29e6-42fe-ba66-ee9387ce0385&amp;name=55289054.jpg"></div>
<br>PDRx Label<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TERBINAFINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">terbinafine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55289-054(NDC:67405-543)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TERBINAFINE HYDROCHLORIDE</strong> (TERBINAFINE) </td>
<td class="formItem">TERBINAFINE</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AN;543</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55289-054-42</td>
<td class="formItem">42  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077919</td>
<td class="formItem">06/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>29be5c0e-2f35-4f14-b2d7-83fb2c2fcb74</div>
<div>Set id: aa9f660f-29e6-42fe-ba66-ee9387ce0385</div>
<div>Version: 3</div>
<div>Effective Time: 20110811</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
